DNA-to-IND program for ADCs

DNA-to-IND program is designed to streamline ADC development by combining mammalian expression, bioconjugation, and drug product development and manufacturing within a single program. Through a platform-based approach, ADC sponsors can reach their IND-enabling CMC package in as little as 13 months while reducing complexity across development activities.

An integrated ADC CDMO helps reduce development complexity by bringing together expertise across antibody development, bioconjugation, analytical services, and drug product manufacturing. Through DNA-to-IND, Lonza provides a coordinated end-to-end supply solution that helps mitigate development risks and supports a more efficient path toward IND submission.

Yes. DNA-to-IND program integrates activities spanning mammalian expression, bioconjugation, drug substance development, and drug product development and manufacturing. This enables customers to access a streamlined development pathway through a single coordinated program.

DNA-to-IND program combines mammalian expression, bioconjugation, analytical platform capabilities, and drug product development and manufacturing into one integrated offering. The program is designed to support customers throughout the CMC journey from DNA through IND-enabling activities.

Yes. While the program uses a standardized platform approach to help accelerate development timelines, Lonza can tailor the technical scope and timelines based on the molecule profile, conjugation requirements, concentration ranges, and overall development objectives of the customer.

Lonza helps mitigate ADC development risks through an integrated network that combines decades of expertise in mammalian expression, bioconjugation, highly potent payload linker and drug product development and manufacturing. Bringing these capabilities together within a single program can simplify coordination and reduce project complexity.

Lonza's DNA-to-IND program combines speed, quality, and efficiency within a single development framework. By integrating antibody expression, payload linker, bioconjugation, analytical support, and drug product manufacturing, Lonza offers customers an end-to-end solution designed to accelerate the path from DNA to IND.